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RESULTS: 2,657 patients were included in this analysis.
Initial and overall mean daily doses were 12.2 and 13 mg
for olanzapine, 5.2 and 5.4 mg for risperidone, and 13.9
and 13.6 mg for haloperidol. Median daily doses were 10
mg for olanzapine, 6 mg for risperidone, and 10 mg for
haloperidol. Significantly (p 	 0.001) lower proportion of
olanzapine-treated patients (36.9%) experienced EPS than
risperidone (49.6%) and haloperidol (76.0%) patients.
Significantly (p 	 0.001) lower proportion of olanzapine-
treated patients (47.8%) experienced any adverse event
than risperidone (57.2%) and haloperidol (79.8%) pa-
tients. Significantly (p  0.05) greater proportion of olan-
zapine-treated patients (37.3%) were responders than ris-
peridone patients (31.5%). Patients who had an initial
CGI 	5 had significantly (p  0.001) higher overall mean
daily doses than patients with an initial CGI 5. Signifi-
cantly (p  0.001) lower proportion of olanzapine-treated
patients (10.2%) were receiving concomitant anticholin-
ergic medication at the end of the study than risperidone
(19.9%) and haloperidol (44%) patients. Significantly (p 
0.001) lower proportion of olanzapine-treated patients
(18.4%) were receiving other antipsychotics at the end of
the study than risperidone patients (25.6%).
CONCLUSION: Mean daily doses from a naturalistic set-
ting were consistent with recommendations based on clini-
cal trials. Olanzapine-treated patients were less likely to
experience EPS, any adverse event, or use of anticholin-
ergic medications than risperidone and haloperidol pa-
tients were. Olanzapine-treated patients were less likely to
receive other antipsychotic medications and more likely to
experience a response than risperidone patients.
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OBJECTIVES: A pharmacoeconomic analysis of schizo-
phrenia treatment with olanzapine, risperidone and halo-
peridol in Germany.
METHODS: A decision model, which included clinical
parameters, that was previously developed by an interna-
tional expert panel was used. Medical resource utiliza-
tion and costs in Germany were determined by a German
expert panel and integrated into the model. Subse-
quently, a cost analysis, a cost-effectiveness analysis and
a cost-utility analysis were performed.
RESULTS: The total costs per patient for 5 years were
highest for risperidone (DM 123 004). Total costs for ha-
loperidol were DM 121 868 and total costs for olanzap-
ine amounted to DM 119 572. Cost-effectiveness of ris-
peridone and olanzapine compared to haloperidol was
better by the factor 2.3 and 2.5, respectively. The costs
per quality-adjusted-life-year were lowest for olanzapine
followed by risperidone and haloperidol.
CONCLUSION: If total costs are considered, the high
medication costs of new antipsychotics are compensated
by savings due to better efficacy in treatment of negative
symptoms and less relapses.
PCN4
A COMPARISON OF ADULT MIGRAINE 
TREATMENT REGIMENS IN A MANAGED
CARE POPULATION
Eaddy M1, Mcloney A2, Margraf T3, Okamoto L2
1University of South Carolina, Columbia, SC, USA; 2NDC 
Health Information Services, Phoenix, AZ, USA; 3PharMetrics, 
Inc., Boston, MA, USA
OBJECTIVES: To compare costs and characteristics of
migraine patients receiving triptan therapy versus those
not receiving triptan therapy.
METHODS: All patients possessing a migraine diagnosis
(ICD-9-CM  346) in the PharMetrics Integrated Out-
comes Database over the age of 18 between January 1,
1997 and March 31, 1998 were eligible for inclusion. Sub-
jects were required to be in the database for at least 3
months prior to and 3 months following the index date.
Any subject receiving migraine treatment prior to their
first diagnosis was excluded from the study. Subjects were
categorized as being in either the triptan or non-triptan
treatment groups based on the presence of a triptan pre-
scription during the 90 days following their index date.
Subject demographics, comorbidities and utilization of
other migraine treatments were assessed, and compared
across treatment groups. Charges were captured over a 90-
day period following the index date.
RESULTS: A total of 8,018 patients met the inclusion cri-
teria. Approximately 85% were female and the mean age
was 41.62 (Std. Dev  12.64). Over 90% did not receive a
triptan prescription within 90 days of the index date. Hy-
pertension was less commonly observed in triptan users;
all other comorbidities occurred equally in both groups.
Triptan users were more likely to consume other anti-
migraine drugs than non-triptan users. Costs were very
similar in triptan users (mean  $1751 Std. Dev.  4142)
and non-triptan users (mean  $1613 Std Dev 5193).
CONCLUSIONS: Triptans did not appear to be com-
monly prescribed following an initial migraine diagnosis.
Despite increased anti-migraine drug usage in triptan us-
ers, costs between triptan and non-triptan users were very
similar.
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